Selected article for: "fusion process and membrane fusion"
Author: Shuai Xia; Meiqin Liu; Chao Wang; Wei Xu; Qiaoshuai Lan; Siliang Feng; Feifei Qi; Linlin Bao; Lanying Du; Shuwen Liu; Chuan Qin; Fei Sun; Zhengli Shi; Yun Zhu; Shibo Jiang; Lu Lu
Title: Inhibition of SARS-CoV-2 infection (previously 2019-nCoV) by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
  • Document date: 2020_3_12
    • ID: j5bepvvw_25
    Snippet: The 6-HB structure formed by HR1 and HR2 regions in the S2 subunit of HCoVs 378 plays a key role during the viral membrane fusion process, which makes it one of the 379 most important targets for drug design. In previous studies, we have found that HR1 380 and HR2 of SARS-CoV-2 could form a stable coiled-coil complex, but the detailed 381 conformations remain unknown. According to the X-ray crystallographic analysis of 382 the complex formed by H.....
    Document: The 6-HB structure formed by HR1 and HR2 regions in the S2 subunit of HCoVs 378 plays a key role during the viral membrane fusion process, which makes it one of the 379 most important targets for drug design. In previous studies, we have found that HR1 380 and HR2 of SARS-CoV-2 could form a stable coiled-coil complex, but the detailed 381 conformations remain unknown. According to the X-ray crystallographic analysis of 382 the complex formed by HR1 and HR2 of SARS-CoV-2 (Fig. 2b) , it is a typical 6-HB However, instead of weakening the interaction between HR1 and HR2, such unilateral 387 difference seems to form new interactions in some regions and enhance the existing 388 ones in other regions (Fig. 3) . When K991 in SARS-CoV HR1 was replaced with 389 author/funder. All rights reserved. No reuse allowed without permission.

    Search related documents:
    Co phrase search for related documents
    • crystallographic analysis and important target: 1
    • crystallographic analysis and key role: 1
    • drug design and fusion process: 1, 2, 3, 4, 5
    • drug design and important target: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • drug design and key role: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • drug design and key role play: 1, 2, 3
    • drug design and membrane fusion process: 1, 2
    • drug design and new interaction: 1, 2
    • drug design and previous study: 1, 2, 3, 4, 5
    • drug design and unknown remain: 1, 2, 3
    • drug design important target and important target: 1, 2, 3, 4
    • drug design important target and key role: 1
    • fusion process and important target: 1, 2, 3
    • fusion process and key role: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • fusion process and membrane fusion process: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • fusion process and new interaction: 1
    • important target and key role: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • important target and membrane fusion process: 1, 2
    • important target and previous study: 1, 2, 3